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Abstract  
Background: The Self-Controlled Case Series (SCCS) method has been widely used for 
hypothesis testing, but there is limited evidence of its performance for safety signal detection.  
Objective: To evaluate SCCS for signal detection on recently approved products.  
Methods:  A retrospective study covered the period after 3 recently marketed drugs were 
launched through Dec 31st, 2010 using The Health Improvement Network (THIN), a UK 
primary care database, and Optum, a US claim database.  SCCS method was applied to examine 
5 heterogenous outcomes with desvenlafaxine and escitalopram and 6 outcomes with 
adalimumab for Signals of Disproportional Recording (SDRs) - lower 95% bound of incidence 
rate ratio (IRR) estimate greater than 1. Multiple design choices were tested and the trend in IRR 
estimates over calendar time for one drug event pair was examined.   
Results:  All 6 outcomes with adalimumab, 3 of 5 outcomes with desvenlafaxine, and 4 of 5 
outcomes with escitalopram had SDRs. SCCS highlighted all acute events in the primary 
analysis but was less successful with slower onset outcomes. Performance varied by risk period 
definition. Changes in IRR estimates over quarterly intervals for adalimumab showed an SDR 
within 9 months of drug launch.  
Conclusion:   SCCS shows promise for signal detection: It may highlight known associations for 
recent marketed products and with potential for early signal identification.  SCCS performance 
varied by design choice and nature of both exposure and event pair.  Future work is needed to 
determine how effective the approach is in prospective testing and determining performance 
characteristics of the approach. 
Key points  
 SCCS is a promising approach for signal detection in real world data, highlighting known 
associations for products with limited time of market penetration. 
 SCCS may offer potential for early signal identification of drug safety.   
 SCCS provides most promising performance with the design choices of “new case” as 
case definition and “Exposure duration” approach for defining risk period, as well as the 
applications for acute events.  
 
  
1. Introduction  
 
Secondary use of electronic healthcare records (EHR) including electronic medical records 
(EMRs) and insurance claims data for hypothesis testing studies has been done for many 
decades [1-4]. Signal detection activities to identify potential drug safety issues has 
historically focused primarily on spontaneous reports[5], but more recently EHRs have also 
been investigated for their utility [6-10].  
The Self-Controlled Case Series (SCCS) method, proposed by Farrington (1995) [11], is 
widely used for assessing vaccine and drug safety for formal hypothesis testing studies [12-
16] and there is growing interest in its potential application with EHR data for signal 
detection [7, 10, 17-22].  A central challenge in signal detection method development is 
testing performance[5].  Much of the testing of SCCS has been against reference sets 
developed by Observational Medical Outcome Partnership (OMOP) [7, 10, 18-22]. OMOP 
testing showed promising characteristics of the SCCS method, with performance assessed as 
similar, or better, than other methods [19, 22]. One similarity across all reference sets is their 
overwhelming focus on established medicinal products. It is not clear that findings on 
established products generalize to newer molecular entities. For a newly marketed medicine, 
its product uptake, the changes in the patient characteristics and drug utilization pattern over 
time will be different from mature products [19], thus, it is necessary to explore how the 
performance of SCCS is applied to a newer medical product.    
In this study, we implemented SCCS in a signal screening framework for three relatively new 
drugs to the market: Humira (Adalimumab, AbbVie Inc., Chicago, US; FDA approval in Dec 
2002 and EMA approval in September 2003), Pristiq (desvenlafaxine, Pfizer Inc., New York, 
US; FDA approval in Feb 2008), and Lexapro (Escitalopram oxalate, Forest Laboratories, 
Inc., St. Louis, US; FDA approval in Aug 2002 and EMA approval in June 2002).   
 
2. Method 
 
2.1 Study design  
 
This study is a retrospective active surveillance database study. The study covers the period 
after each study drug was launched through Dec 31st, 2010. We chose to study drugs that 
have been marketed for several years as this means they have a well-established safety 
profile. However, we would also be able to assess the performance of safety surveillance 
during the period of early marketing. Specifically, the study period is 1/1/2002- 12/31/2010 
for Adalimumab; 2/1/2007 -12/31/2010 for desvenlafaxine;  8/1/2001-12/31/2010 for 
escitalopram in OPTUM; and 6/1/2001 -12/31/2010 for escitalopram in THIN to allow 12 
month enrolment for those patients entered in the database right after the drug approval date.  
All patients having valid data in the databases during the study period were eligible for 
inclusion.  
2.2  Data sources 
 
This study used The Health Improvement Network (THIN), a UK EMR database, and Optum, 
a US claim database.   
THIN data contains de-identified primary care EMR data provided by IMS Health [23].  
THIN data covers ~6% of the population in the UK and is broadly representative. It holds 
comprehensive demographic, clinical and prescribing data. The September 2011 version of 
THIN data was used for this analysis, which covers ~9 million unique patients.    
Optum is a longitudinal US claims database from United Healthcare (UHC) insurance plans 
that represents approximately 3–4 % of the geographically diversified population in US [24]. 
The database contains longitudinal de-identified patient data that include registration, 
pharmacy claims, medical claims, inpatient and outpatient services utilization, and 
procedures, and lab results. The 2010 Q4 version was used for the analysis which covers ~44 
million unique patients.  
2.3  Exposure 
 
Much signal detection testing has focused on screening relatively large numbers of drug-
outcome pairs and looked at quantitative performance of characteristics compared to external 
reference sets rather than extensive evaluation of the pairs [10, 18-19, 21-22].  We therefore 
decided to look in depth at a small number of drug-outcome pairs with a focus on an area of 
relatively recent therapeutic innovation.  To help with generalizability, we initially selected 
two medications in two different therapeutic areas: desvenlafaxine, an antidepressant drug, 
and adalimumab, a rheumatoid arthritis (RA) drug with a focus on RA indication.  At 
planning stage we anticipated both drugs would be well captured in both Optum and THIN 
databases. When we initiated the study we discovered that the coverage was limited to the 
US Claims for desvenlafaxine. Upon further analysis it became clear that no bDMARDs 
were well captured in THIN so we elected to not conduct a THIN SCCS analysis on 
adalimumab. For transparency we elected to continue to study these two drugs using Optum 
database but to also include some similar drugs that were captured in both databases. Thus, 
escitalopram was added to the study using both THIN database and Optum database. 
National Drug Code (NDC), a US drug coding system, was used for defining the exposures 
in Optum data and BNF codes/ Mulitlex codes, a UK drug coding system, were used for 
defining the exposures in THIN data.    
 
2.4 Outcome 
Five outcomes were selected for studying the association with desvenlafaxine and 
escitalopram: Hypertension, Orthostatic hypotension, Proteinuria, Hyperlipidemia, and 
Fractures (All types). Six outcomes were selected for studying the association with 
adalimumab: Acute Myocardial Infarction (AMI), GI Perforation, Herpes Zoster, Interstitial 
Lung Disease, Lymphoma, and Pneumonia.  The rationale of selecting the outcomes includes 
general importance to drug safety, inclusion of the outcomes in the product label, literature of 
safety concerns in the same drug class  (antidepressants - fracture), and feasibility for 
studying the outcomes  using Optum or THIN data. Specifically, we first selected the events 
of interests for desvenlafaxine and adalimumab, two drugs initially planned to be studied.  
All events for these two drugs were labelled except for fracture with desvenlafaxine which 
was discussed in the literature as a safety concern in the same drug class [25-28]. As 
escitalopram, an antidepressant, was added later to allow the use of both databases, we have 
kept the same events of interest for this drug same as for desvenlafaxine. The outcomes were 
defined using ICD-9 codes in Optum data (Table 1, Electronic Supplementary Material 
(ESM) #1 and READ codes in THIN data (Table 2, ESM #1).   
 
2.5  Analysis Methods 
The SCCS model assuming events arise from a non-homogeneous Poisson process includes 
individuals who have had both the exposure and outcome of interest regardless of the timing 
and order of exposure and outcome [10, 15, 18-19, 22, 29].  SCCS method does not require a 
reference exposure group, as each patient is both exposed and unexposed and acts as their 
own reference for comparison, which implicitly controls for time-fixed covariates.  Incidence 
rate ratios (IRR) are calculated by comparing the rate of events in a given post-exposure 
period (risk period) to the rate of events in unexposed periods absent of the exposure (all 
other observed time) [15-16]. In a signal screening framework, statistical uncertainty is 
examined based on the 95% confidence interval of the IRR estimates. Specifically, when the 
lower 95% bound of IRR estimate is greater than 1(i.e. IRR025 >1)  this is considered a 
positive finding and is a Signal Of Disproportional Recording  (SDR) analogous to SDRs in 
spontaneous reporting which are findings of potential interest that have not undergone 
clinical review to be considered signals of suspected causality [30-31]. Key assumptions for 
SCCS method include conditionally independent events and events conditionally 
independent of exposure. Accurate dating of outcomes is also important, and we 
acknowledge some of the outcomes included here are difficult to date e.g. lymphoma and 
hyperlipidemia. Nonetheless, they are included to test the resilience of the method to this 
assumption, as there is a lack of evidence about the impact of violating SCCS assumptions.  
The details of SCCS method has been described extensively elsewhere [15, 18-19]. We 
implemented SCCS (Figure 1.) using OMOP standard SAS programming procedures as 
developed by the researchers of Columbia University and published on OMOP’s website for 
this study [32]. The code was further modified as needed for all analyses conducted here, 
including the ‘Exposure Duration’ approach using SAS 9.2 version. 
 
2.6 Design Choices  
 
The selection of analytic design choices would impact the implementation of the SCCS 
method testing [19, 33].  For this study, the design choices selected for the primary and 
secondary analyses are summarized in Table 1.   
We only looked at the 1st occurrence of each outcome of interest to capture incident event in 
this study.  We then focused on the events with the requirement of a 12 month event free 
enrolment period (defined as “New” cases) in the primary analysis.    In a secondary analysis, 
we also investigated the events without the requirement of a 12 month event free enrolment 
period (defined as “All cases”), recognizing that this selection means we may sometimes 
include events that are not incident [34]. The “All Case” definition was included in the 
OMOP SCCS package.    
In a drug safety signal detection framework, appropriate risk period selection may differ from 
a formal hypothesis-testing study in epidemiology. There is limited literature on the impact 
of such selection on method performance for signal detection, although OMOP conducted 
some initial evaluation. Two approaches to risk period selection are compared. 1). “OMOP” 
approach (Figure 2.1 – 2.5): risk period is defined as exposure start plus 30 days (fixed 
period), and exposure duration plus a variable subsequent period (0, 30, 60 or 90 days) thus, 
5 risk periods are selected and all other time is considered baseline (varied by risk period).  
The risk period “exposure duration plus 30 days within the end of exposure” was selected in 
the primary analysis, allowing the risk of an outcome to be elevated at any time during 
exposure as well as the 30 day initial surveillance window. 2) A modified approach - 
“Exposure Duration” approach (Figure 3): risk period is exposure duration. Three 30 day 
washout periods (1-30, 31-60, 61-90 days) after estimated end of exposure are analyzed 
separately as potential exposure windows where the drug effects may still exist. Risk and 
washout periods are each compared with the same baseline to obtain incidence rate ratio 
(IRR) estimates.  Initiation of a new medication tends to occur on the day a patient visits their 
doctor. Patients will often notify their doctor of recent medical events at the same visit, and 
therefore events recorded on the date a new medication is started will often predate the start 
of treatment. Thus, the first day of treatment is not included in risk time, to minimize 
misclassification errors.  
As another secondary analysis, we also examined the change in IRR estimates over calendar 
time from SCCS model using the parameters in the primary analysis through a single drug 
event pair highlighted with a high IRR during the first phase of analyses to better understand 
if observational data might be used for earlier signal identification.   
3. Results  
 
An overview of the demographic characteristics of the patients included in the anlysis per 
drug-outcome pair is presented in Table 2.  Total number of patients per drug-outcome varied 
by nature of the outcome (i.e. rare or common), database, and length of drug on the market.  
The most common outcomes in this analysis are hyperlipidemia and hypertension while the 
least common outcomes are AMI and lymphoma.  Overall, females had higher proportion of 
the conditions than males except for AMI, and average age at 1st drug exposure is similar to 
the average age at 1st condition. 
 
3.1 Primary Analysis  
 
Figure 4 shows results for all exposures and outcomes using the primary approach. All 6 
outcomes of interest (i.e. AMI, GI perforation, Herpes zoster, interstitial lung disease, 
lymphoma, and pneumonia) associated with adalimumab were highlighted as potential safety 
concerns with IRR025 >1 or SDR.  Three of the 5 outcomes of interest (i.e. Fractures, 
orthostatic hypotension, and proteinuria) were found to have SDRs associated with 
desvenlafaxine (i.e. IRR025 >1). Two pairs without SDRs were: Hypertension and 
hyperlipidemia.  For Escitalopram, except for hypertension, 4 outcomes (i.e. fractures, 
hyperlipidemia, orthostatic hypotension, and proteinuria) had SDR on both THIN and Optum 
data. Hypertension had no SDR in neither THIN nor Optum.  The IRR and 95% CI for each 
of these drug-outcome pairs are listed in Table 3.      
 
3.2 Secondary Analysis 
 
Choice of Case Inclusion Criteria  
Figure 5 shows the comparison of the results of “All Cases” and “New Cases”. When using 
criteria of “All Cases”, the SCCS method not only produced consistenly lower estimates 
across all drug-outcome pairs and databases, but also fewer SDRs. For “all cases”, SCCS 
highlighted 50% of outcomes of interest (3 pairs) associated with  adalimumab on Optum 
data, none of outcomes of interest associated with desvenlafaxine on Optum data, and 40% of 
outcomes of interest (2 pairs) associated with escitalopram  on both THIN and Optum data.    
Choice of Risk Periods   
 
Figure 6 indicates that SCCS method performance varied by the choice of risk periods when 
using the OMOP approach.  In general, a major difference was seen when defining the 
exposed period as the first 30 days of drug exposure (i.e. fixed period) only: 60% or more 
estimates on adalimumab, desvenlafaxine, and escitalopram in Optum data, and 40% of 
estimates on escitalopram in THIN data were smaller than seen in the primary analysis. 
Increasing the number of days included in the risk period post-treatment led to an increase in 
IRR estimates of the majority of pairs in Optum data.  
As shown in Figure 7 “Exposure Duration” approach generated often higher estimates of the 
IRR in the 1st or 2nd washout period compared with those when  risk period was the estimated 
duration of treatment alone. For example, consistently higher estimates of the IRR during the 
“first washout period” than risk period as well as other wash out periods were observed 
across 6 adalimumab - outcome pairs.  However, the estimate of the IRR was generally lower 
in the final washout period (days 61-90) than during exposure. Wider 95% CI of the 
estimates in the 3 washout periods were observed due to fewer events counted as incident 
cases.   
 Comparing the IRR estimates between the OMOP and Exposure Duration approaches 
(across figures 6 and 7 respectively) where the risk period were both set as exposure duration 
only, the Exposure Duration approach generated consistently higher estimates for all 6 
adalimumab - outcome pairs and highlighted one more SDR (i.e. lymphoma);  the estimates 
for the Exposure Duration approach were either similar to or slightly higher than those 
obtained with the OMOP approach for the desvenlafaxine and escitalopram – outcome pairs. 
Neither method identified escitalopram and hypertension (THIN or Optum); nor 
desvenlafaxine and hypertension or desvenlafaxine and hyperlipidemia (Optum).   
We observed that the Exposure Duration approach highlighted 5 pairs (i.e. Herpes Zoster, 
Lymphoma, and Pneumonia with adalimumab;  Orthostatic Hypotension with desvenlafaxine; 
and Orthostatic Hypotension  with escitalopram in Optum ) with IRR≥2  while no pair with 
IRR≥2 was found using “OMOP” approach regardless the selection of the OMOP risk 
periods. While direction of IRR025 was similar, in general, across the two approaches, some 
discordance from these two aprroaches was observed. For example  the Exposure Duration 
approach identified a SDR (i.e. IRR025 >1) of hypertension with escitalopram in Optum during 
the 1st and 2nd washout period while no SDR  was seen with the OMOP approach.   
Risk over time   
 Figure 8 shows results of IRR of herpes zoster in patients using adalimumab since drug 
launch to end of 2010.  This example allows us to see the changes of IRR over time for this 
drug-outcome pair and understand if observational data may be used for earlier signal 
identification.  Overall, IRR025   were all greater than 1 over time. There were no cases 
reported in the 1st quarter of the 1st year after the drug approval date.  However, the IRR 
estimates in the following three quarters since the drug launch were substantially higher 
though the event numbers were low (IRR=6.15 in 2003 Q2 and IRR=4.40 in 2003 Q4).  The 
estimates continued the decline over next two years from IRR=3.35 in 2004 Q1 to IRR=2.01 
in 2006 Q2 before they were stabilized during the period from 2006 Q2 to 2010 Q4 with an 
IRR of approximate 2.0 for all estimates.        
4. Discussion  
 
Our findings suggest that SCCS may be useful for safety signal detection in EHRs; most 
known adverse drug reactions associated with desvenlafaxine and escitalopram for 
depression and adalimumab for RA were correctly identified in the framework we 
implemented using both THIN and Optum data. It also appears that early identification of 
previously unknown safety signals may be possible shortly after a new product is launched. 
The IRR estimates were partly dependent on design choices with respect to defining the “at 
risk” period.  
The self-controlled case series can be implemented in many different ways in terms of time 
at risk, control time and wash out periods (i.e. neither control nor exposed time) and as it is 
also volatile to time varying confounding and other factors these design choices were 
anticipated to affect signal detection capability greatly.  
This study builds on previous work by OMOP by assessing drugs near their time of launch, 
and by focussing on a few specific drug-event pairs, some of which we anticipated SCCS 
should perform well on, and some not, we have been able to uncover more insights into the 
applicability of the SCCS and its implementation for signal detection. 
The vast majority of pairs were highlighted in the primary analysis.  In particular, SCCS was 
able to highlight all acute events in the primary analysis. We would not normally expect to 
use SCCS to study chronic condition with uncertain onset date.  However, our highlighting of 
adalimumab- lymphoma, an event in the black box warnings for adalimumab, supports a 
position that the method may sometimes be robust when the signal is very strong even 
though  some assumptions are violated [35-36].  Future work needs to determine how 
effective the approach is for highlighting the previously unaccepted drug event pairs and 
determining performance characteristics of the approach including the robustness in handling 
the chronic diseases for which the assumptions for the SCCS method might be violated. 
Hypertension and hyperlipidemia for desvenlafaxine were consistently not highlighted. Both 
are outcomes with slow onset that can only be identified through testing, requiring a visit to 
the general practitioner (GP) to have taken place. Escitalopram shares the same pattern for 
hypertension and the SDR of hyperlipidemia-Escitalopram was weak. We observed similar 
patterns for Escitalopram in both THIN and Optum: both of which are outcomes we 
anticipated SCCS would not be suitable for.  
We selected labelled outcomes for the RA drug adalimumab and antidepressant 
desvenlafaxine, as well as fracture for desvenlafaxine, an outcome widely associated with 
antidepressants and widely studied in secondary databases studies [25-28]. We selected the 
same outcomes for escitalopram as for desvenlafaxine for comparability. Outcomes were 
selected to have varying properties (acute vs. chronic etc) and with varying evidential support 
for capability of accurate capture in Claims and EMRs. We note that five pairs (Herpes 
Zoster, Lymphoma, and Pneumonia with Adalimumab; Orthostatic Hypotension with 
desvenlafaxine; and Orthostatic Hypotension  with escitalopram in Optum) were all 
highlighted by the “Exposure Duration” approach with an IRR≥2. Some argue that 
observational studies are more reliable when estimates greater than 2 are achieved [37-39], 
and in signal detection ranking based on SDR is often used to prioritise of pairs for further 
consideration [5].   
In spontaneous reporting quantitative analysis it is well established that highlighted pairs 
require clinical review to be considered signals of suspected causality [5]. Outputs from 
quantitative signal detection in longitudinal observational databases similarly require further 
investigation to be considered signals as the coarse design choices required for 
implementation in a signal detection framework mean that many of the biases prevalent in 
observational data will not have been adequately controlled for. 
In testing case inclusion criteria we found that solely including new cases in the case 
definition gave higher IRR estimates than including ‘all cases’. This is not surprising as cases 
close to registration are not always incident, but reflect recording of previous events or 
prevalent conditions [34]. While it is accepted that studying new cases rather than ‘all cases’ 
is appropriate in pharmacoepidemiological studies, we considered it worth investigating in a 
signal detection context because the dilution effect of including prevalent events might have 
been outweighed by the extra power of including more cases. The results however support 
the idea that the flawed “all case” design leads to lower estimates due to the inclusion of 
events recorded around the time of patient registration. As these events tend more often to 
occur during baseline periods of observation time, they will lead to an overestimate of the 
baseline event rate and hence would bias estimates of relative effects in a way that would 
make exposed time appear less harmful or even beneficial. Therefore we recommend for 
signal detection that ‘new cases’ should be used for SCCS signal detection. 
In terms of risk period selection our results support a position that there is no uniformly 
appropriate exposure time and baseline time in a signal detection framework [33]. Overall, 
our results suggest that taking an “Exposure Duration” approach to defining the risk period 
and separate consideration of wash out periods performs well. However the finding that 
elevated IRR estimates representing SDRs were found during the wash out periods including 
sometimes 60-90 days, suggests that wash out period inclusion is of importance. SCCS 
studies have used wash out periods of, for example, 75 or 91 days [28,40] to include this 
apparent post-treatment period which can include some ongoing exposure.  Our results 
suggest that the “Exposure Duration” risk period selection offers good potential for signal 
detection as it optimizes the distinction between exposed (high risk) time and baseline time. 
This would explain the larger effect estimates seen with the Exposure Duration approach 
compared with the OMOP approach as it is less likely that a risk period will erroneously 
include unexposed time, or the baseline includes time with persisting drug effect.   
When examining the change in IRR estimate over quarterly intervals across the study period 
for adalimumab with herpes zoster we see that the estimate is immediately positive, albeit 
with wide confidence intervals, and then settles to a lower but still positive estimate. The 
significantly higher IRR in the first couple years since launch might indicate volatility of 
estimates newly after approval or a bias towards more recording of clinical events in people 
taking newly licensed treatments.  In the package insert created in September 26 2003, other 
infrequent serious adverse events occurring at an incidence of less than 5% in patients treated 
with adalimumab in clinical trial included herpes zoster [41].  However, the frequency of the 
event in placebo group was not reported or compared and it could be interpreted that the 
causal nature of the event was uncertain at this stage.  The finding that all drugs in this class 
are associated with an increased risk of  herpes zoster was published until 2009 [42].  This 
suggests the potential of the SCCS method for early signal detection and the potential value 
in monitoring drug safety sequentially in longitudinal observational databases. Tracking the 
date when specific adverse reactions are added in the label would be helpful to evaluate the 
usefulness of SCCS for prospective, early signal detection. 
A limitation of the study was that we focused our analysis on a more extensive analysis of a 
small number of drug event pairs for only a handful of drugs, which limits generalizability. 
We didn’t look at any negative control outcomes, so we can’t comment on specificity – 
further work will need to assess the number of false positive findings from the approach. 
While SCCS method implicitly controls time invariant variables, we did not adjust age or 
other time varying covariates in the model.  From a signal detection perspective, inclusion of 
fewer covariates is often reasonable or preferred [43] as confounders and effect modifiers are 
unknown and can be better treated in post-hoc analyses. For relatively long observation 
periods, could easily be added to the model.  Key assumptions for the SCCS method include 
conditionally independent events and events conditionally independent of exposure.  While 
selecting first incident event in the analysis helps satisfy the assumption of “conditionally 
independent events”, the assumption of “events conditionally independent of exposure” is 
likely violated (at least for some of pairs) as it is difficult to expect any event of interest does 
not have an impact on the future exposure of interest in the study. Nonetheless, if the effect 
on subsequent exposure is short lived the impact on effect estimates may not be great. Our 
results support a perspective that different approaches are needed when considering different 
outcomes and potentially which methods should be used to best detect emerging signals. 
Much in the same way research suggests that some outcomes are more suited to detection in 
spontaneous reports and others in longitudinal observational databases [8]; similarly 
outcomes could be stratified into groups with similar properties (acute vs. chronic, transient 
vs. persistent, etc.), and signal detection approaches targeted at the specific groups 
individually, using a similar approach to epidemiological design proposed by mini- Sentinel 
[44]. In order to conduct method testing and better understand the capabilities of SCCS for 
signal detection, we have focused on a detailed analysis of labelled effects. In practice as 
hypothesis free signal detection for unexpected effects is increasingly conducted some 
further triage to focus most efforts on discovering outcomes often anticipated to have most 
public health importance and be reliably - or more effectively - detected in longitudinal 
observational databases may be warranted (e.g. those with biological plausibility, common 
ADRs, outcomes listed in risk management plans as potential safety concerns etc.). One 
example is using the SNIP criteria proposed for filtering spontaneous reports [45], focusing 
on WHO Critical terms [46] or those proposed as of particular value to screen for in previous 
longitudinal observation data research initiatives [9]. 
5. Conclusion  
 
 Our work shows that Self Controlled Case Series is a promising approach for signal 
detection, highlighting known associations for products with limited time for market 
penetration. We have shown which design choices look most promising and reaffirmed that 
performance of the Self Controlled Case series varies by the nature of both exposure and 
event pair and their anticipated association; this impact being important to consider in signal 
detection where there is necessarily less scope for tailored analyses. Future work needs to 
determine how effective the approach is for highlighting the previously unaccepted drug 
event pairs and determining performance characteristics of the approach. 
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